News on technologies and applications for point-of-care testing.
The firm said that its point-of-care antigen testing platform uses high-frequency bulk acoustic wave sensors to detect SARS-CoV-2 at low limits of detection.
Building on recently published NIH-funded work on rapid antigen testing, the CDC and NIH have launched a study to evaluating community-wide home testing.
The firm said its rapid antigen test provided 97.3 percent sensitivity and 99.6 percent specificity in clinical studies, and it is developing a saliva-based version.
Lucira Health's at-home molecular test received Emergency Use Authorization in November for prescription use.
The technology underlying the test was developed by Dutch firm Minicare, which was acquired by Siemens in 2019.
